Association between incretin-related drugs and fractures in patients treated with pioglitazone: A pharmacovigilance study using the FDA Adverse Event Reporting System
Our results suggest that incretin-related drugs, especially GLP-1RAs, reduce the risk of fractures in patients treated with diabetes medications such as pioglitazone.
Authors
- Katsuhiro Ohyama (ORCID: https://orcid.org/0000-0001-6307-577X)
- Noriko Abe (ORCID: https://orcid.org/0000-0001-8314-6619)
- Yusuke Hori (ORCID: https://orcid.org/0000-0002-5921-3479)
- Takumi Okamoto
Publication Details
- Journal
- International Journal of Clinical Pharmacology and Therapeutics
- Published
- 2025-10-22
- DOI
- https://doi.org/10.5414/cp204789
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00